Non-small cell lung cancer (NSCLC) comprises
approximately 85% of all lung cancers. Somatic
mutations in the epidermal growth factor receptor
tyrosine kinase (EGFR-TK) domain influence the
treatment with EGFR-TK inhibitors.
First-line TK inhibitors, such as erlotinib and
gefitinib, are effective anti-cancer drugs in NSCLC
patients carrying activating EGFR mutations.
Conversely, patients carrying the resistance
mutation T790M do not benefit from first-line
EGFR-TK inhibitor therapy.
Identification of EGFR mutations allows the
decision whether an EGFR-TK inhibitor is suitable
for use in NSCLC therapy.